ISRCTN07447845已完成2 期
Phase II trial of combination therapy with oxaliplatin and capecitabine in patients with advanced oesophageal cancer
Erasmus Medical Centre (The Netherlands)0 个研究点目标入组 51 人开始时间: 2007年2月27日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 51
研究概览
简要总结
2007 Results article in https://doi.org/10.1038/sj.bjc.6603750 (added 26/08/2021)
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Metastatic or local-regional unresectable adenocarcinoma or squamous cell carcinoma oesophagus or gastric junction
- •2. At least one unidimensional measurable lesion greater than 20 mm (conventional), or greater than 10 mm (spiral)
- •3. World Health Organisation (WHO) grade zero to two
- •4. Adequate haematological, renal and hepatic functions
排除标准
- •1. Prior treatment with oxaliplatin or capecitabine; prior (neo)-adjuvant treatment for metastatic disease is allowed if completed at least six months prior to study start
- •2. Malabsorption syndrome or inability to take oral medication
- •3. Pre-existing motor or sensory neurotoxicity greater than grade one
- •4. Active infection
研究者
相似试验
已完成
不适用
Phase II trial of combination therapy with oxaliplatin and capecitabine in patients with advanced esophageal cancer.NL-OMON20867/A43
未知
2 期
Phase II clinical study on combination of oxaliplatin (L-OHP) and S-1 in advanced / recurrent gastric cancer untreated with chemotherapyGastric cancerJPRN-jRCT2080220365Yakult Honsha Co.,Ltd.
已完成
2 期
Endometrial Cancer - LOHP Alone and With 5FUEndometrial CancerNCT00612495Sanofi31
进行中（未招募）
不适用
Phase II trial of second line therapy with Oxaliplatin and Pemetrexed in patients with advanced pancreatic cancer - Pemetrexed_OxaliplatinoAdvanced pancreatic cancer patientsMedDRA version: 14.1Level: PTClassification code 10059326Term: Pancreatic carcinoma stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2006-001272-21-ITAZIENDA OSPEDALIERO-UNIVERSITARIA S. MARIA DELLA MISERICORDIA DI UDINE
已完成
1 期
Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or LymphomasChildhood Burkitt LymphomaChildhood Central Nervous System Germ Cell TumorChildhood Diffuse Large Cell LymphomaChildhood Grade III Lymphomatoid GranulomatosisChildhood Immunoblastic Large Cell LymphomaRecurrent Childhood Brain Stem GliomaRecurrent Childhood Cerebellar AstrocytomaRecurrent Childhood Cerebral AstrocytomaRecurrent Childhood EpendymomaRecurrent Childhood Grade III Lymphomatoid GranulomatosisRecurrent Childhood Large Cell LymphomaRecurrent Childhood Liver CancerRecurrent Childhood Lymphoblastic LymphomaRecurrent Childhood Malignant Germ Cell TumorRecurrent Childhood MedulloblastomaRecurrent Childhood RhabdomyosarcomaRecurrent Childhood Small Noncleaved Cell LymphomaRecurrent Childhood Soft Tissue SarcomaRecurrent Childhood Supratentorial Primitive Neuroectodermal TumorRecurrent Childhood Visual Pathway GliomaRecurrent Colon CancerRecurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal TumorRecurrent MelanomaRecurrent Nasopharyngeal CancerRecurrent NeuroblastomaRecurrent OsteosarcomaRecurrent Wilms Tumor and Other Childhood Kidney TumorsRecurrent/Refractory Childhood Hodgkin LymphomaUnspecified Childhood Solid Tumor, Protocol SpecificNCT00101270National Cancer Institute (NCI)24